Acute Myeloid Leukemia Coverage From Every Angle
Editor:
Rebecca Olin, MD, MS
Advertisement
Advertisement

Videos

Alba Rodriguez-Meira, DPhil, on a Possible Key to Understanding Leukemic Transformation

Eunice S. Wang, MD: Clinical Perspective: Treatment Options for Patients With FLT3-Mutated AML

Curtis Lachowiez, MD, on Clinical Implications of Using Venetoclax Plus FLAG-IDA in AML

Alice S. Mims, MD, on Clinical Insights Into Effective AML Treatment

Stéphane de Botton, MD, PhD, on AML: The Effect of Olutasidenib on Complete Remissions

Keith W. Pratz, MD, on Reaching Composite Complete Response With Venetoclax/Azacitidine: What It Means for Patients With AML

Mark J. Levis, MD, PhD, on AML: First-in-Human Study of an FLT3 Inhibitor

Alexander E. Perl, MD, on What the Updated AML Guidelines Mean for Clinical Practice

Sara Zarnegar-Lumley, MD, on IDH Mutations and Outcomes in Acute Myeloid Leukemia

Tapan M. Kadia, MD, on Clinical Pearls: Treating AML With CPX-351 Plus Venetoclax

Keith W. Pratz, MD, on Gilteritinib With Induction and Consolidation Chemotherapies in AML

Musa Yilmaz, MD, on Quizartinib Plus Decitabine With or Without Venetoclax for FLT3-ITD–Mutated AML

Ann-Kathrin Eisfeld, MD: Why Do Younger Black Patients With AML Have Poor Outcomes?

Andrew H. Wei, MBBS, PhD, on Safely Administering a Venetoclax-Containing Regimen to Older Patients With AML

Alfonso Bencomo Álvarez, PhD, on Survival Outcomes for Hispanic Patients With Hematologic Cancers Living at the US/Mexico Border

Courtney D. DiNardo, MD, on Clinical Implications of Venetoclax and Azacitidine for Treatment-Naive Patients With AML

Lyndsey Runaas, MD, on AML, Transplants, and COVID-19: Expert Guidance

Lyndsey Runaas, MD: Which Regimens Are Appropriate for Older Patients With AML?

Lyndsey Runaas, MD, on Older Patients With AML: Who Is the Ideal Candidate for Transplant?

Ehab L. Atallah, MD, on AML and COVID-19: Expert Guidance on Administering Venetoclax and TKIs

Ehab L. Atallah, MD, on AML and COVID-19: Expert Guidance on Maintenance Therapy

Andrew H. Wei, MBBS, PhD, on Oral Azacitidine as Maintenance Therapy in AML: Clinical Challenges

Mikkael A. Sekeres, MD, on a Less Aggressive Alternative for Hematologic Malignancies

David P. Steensma, MD, on Talking to Patients With AML About Taking Part in First-in-Human Trials

Abhishek Maiti, MBBS, on Comparing Treatment Regimens for Older Patients With AML

The JNCCN Spotlight

Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.